Ucb SA logo

UCB - Ucb SA Share Price

€81.54 -1.5  -1.9%

Last Trade - 11:15am

Large Cap
Market Cap £13.51bn
Enterprise Value £14.46bn
Revenue £4.60bn
Position in Universe 58th / 847
Unlock UCB Revenue
Relative Strength (%)
1m +0.39%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -27.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
3,876 4,147 4,530 4,632 4,913 5,347 5,572 5,437 +6.6%
+32.7 +67.1 +57.4 +1.1 +4.4 -1.8 +32.2 +1.38
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, UCB SArevenues increased 9% to EUR5.35B. Net income applicable tocommon stockholders excluding extraordinary items decreased7% to EUR732M. Revenues reflect Vimpat segment increase of10% to EUR1.45B, Cimzia segment increase of 5% to EUR1.8B,USA segment increase of 8% to EUR2.76B, UnitedKingdom/Ireland segment increase of 29% to EUR148M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for UCB
Graphical History


UCB Revenue Unlock UCB Revenue

Net Income

UCB Net Income Unlock UCB Revenue

Normalised EPS

UCB Normalised EPS Unlock UCB Revenue

PE Ratio Range

UCB PE Ratio Range Unlock UCB Revenue

Dividend Yield Range

UCB Dividend Yield Range Unlock UCB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
UCB EPS Forecasts Unlock UCB Revenue
Profile Summary

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since January 2, 1987
No. of Shareholders: n/a
No. of Employees: 8,409
Sector Healthcare
Industry Pharmaceuticals
Index BEL 20 , FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 300 , FTSEurofirst 300 Eurozone , FTSEurofirst 300 Ex UK,
Exchange Euronext - Brussels
Shares in Issue 189,025,436
Free Float (0.0%)
Eligible for
UCB Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for UCB
Upcoming Events for UCB
Thursday 29th April, 2021
Ucb SA Annual Shareholders Meeting
Friday 30th April, 2021
Dividend For UCB.BR - 1.2700 EUR
Wednesday 12th May, 2021
Ucb SA at Kempen Life Sciences Conference (Virtual)
Tuesday 25th May, 2021
Ucb SA at Goldman Sachs Group Inc Roadshow (Virtual)
Thursday 29th July, 2021
Half Year 2021 Ucb SA Earnings Release
Frequently Asked Questions for Ucb SA
What is the Ucb SA share price?

As of 11:15am, shares in Ucb SA are trading at €81.54, giving the company a market capitalisation of £13.51bn. This share price information is delayed by 15 minutes.

How has the Ucb SA share price performed this year?

Shares in Ucb SA are currently trading at €81.54 and the price has moved by -2.49% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Ucb SA price has moved by -24.59% over the past year.

What are the analyst and broker recommendations for Ucb SA?

Of the analysts with advisory recommendations for Ucb SA, there are there are currently 5 "buy" , 9 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Ucb SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Ucb SA next release its financial results?

Ucb SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Ucb SA dividend yield?

The Ucb SA dividend yield is 1.07% based on the trailing twelve month period.

Does Ucb SA pay a dividend?

Last year, Ucb SA paid a total dividend of 0.89, and it currently has a trailing dividend yield of 1.07%. Looking ahead, shares in Ucb SA are due to go ex-dividend on 2021-04-30 and the next dividend pay date is 2021-05-04.

When does Ucb SA next pay dividends?

Ucb SA are due to go ex-dividend on 2021-04-30 and the next dividend pay date is 2021-05-04. The historic dividend yield on Ucb SA shares is currently 1.07%.

How do I buy Ucb SA shares?

To buy shares in Ucb SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Ucb SA?

Shares in Ucb SA are currently trading at €81.54, giving the company a market capitalisation of £13.51bn.

Where are Ucb SA shares listed? Where are Ucb SA shares listed?

Here are the trading details for Ucb SA:

Country of listing: Belgium
Exchange: BRU
Ticker Symbol: UCB
What kind of share is Ucb SA?

Based on an overall assessment of its quality, value and momentum, Ucb SA is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Ucb SA share price forecast 2021?

Shares in Ucb SA are currently priced at €81.54. At that level they are trading at 26.99% discount to the analyst consensus target price of 0.00.

Analysts covering Ucb SA currently have a consensus Earnings Per Share (EPS) forecast of 5.719 for the next financial year.

How can I tell whether the Ucb SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ucb SA. Over the past six months, the relative strength of its shares against the market has been -24.33%. At the current price of €81.54, shares in Ucb SA are trading at -9.62% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Ucb SA PE Ratio?

The Ucb SA PE ratio based on its reported earnings over the past 12 months is 19.21. The shares are currently trading at €81.54.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Ucb SA?

Ucb SA's management team is headed by:

Evelyn Diego du Monceau de Bergendal - NEC
Roch Doliveux - NED
Iris Loew-friedrich - EVP
Jean-Christophe Tellier - CMG
Charles-Antoine Janssen - NED
Antje Witte - VPR
Emmanuel Caeymaex - EVP
Cyril Janssen - NED
Pierre Gurdjian - NVC
Charl Van Zyl - EVP
Jean-Luc Fleurial - CHO
Dhavalkumar Patel - EVP
Kirsten Lund-jurgensen - EVP
Bill Silbey - EVP
Sandrine Dufour - CFO
Who are the major shareholders of Ucb SA?

Here are the top five shareholders of Ucb SA based on the size of their shareholding:

Janssen Family Individual Investor
Percentage owned: 35% (68.1m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 8% (15.6m shares)
Vanguard Health Care Fund Mutual Fund
Percentage owned: 5.26% (10.2m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5% (9.73m shares)
FMR Investment Management (U.K.) Limited Investment Advisor
Percentage owned: 3.63% (7.06m shares)
Similar to UCB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.